Immune checkpoint blockade (ICB) inhibitors have transformed the treatment of cancer and have become the frontline therapy for a broad range of malignancies. It’s because they work better than the previous standard of care.
Researchers develop a system of synthetic biosensors to assess the response of cancer therapy
Immune checkpoint blockade (ICB) inhibitors have transformed the treatment of cancer and have become the frontline therapy for a broad range of malignancies. It's because they work better than the previous standard of care.